148 related articles for article (PubMed ID: 31868552)
21. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake T
Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
23. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
24. Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.
Xie QS; Zhang JX; Liu M; Liu PH; Wang ZJ; Zhu L; Jiang L; Jin MM; Liu XN; Liu L; Liu XD
Acta Pharmacol Sin; 2021 Mar; 42(3):470-481. PubMed ID: 32555444
[TBL] [Abstract][Full Text] [Related]
25. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
26. Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Sawangrat K; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2018 Nov; 107(11):2946-2956. PubMed ID: 30053556
[TBL] [Abstract][Full Text] [Related]
27. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
28. Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate.
Tomaru A; Morimoto N; Morishita M; Takayama K; Fujita T; Maeda K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2013; 28(1):71-4. PubMed ID: 22785334
[TBL] [Abstract][Full Text] [Related]
29. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
30. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
31. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Sodhi JK; Liu S; Benet LZ
Pharm Res; 2020 Sep; 37(10):208. PubMed ID: 32996065
[TBL] [Abstract][Full Text] [Related]
32. Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Xenobiotica; 2020 Apr; 50(4):401-407. PubMed ID: 31317804
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein.
Miyamoto R; Nozawa T; Shiozuka K; Tabata K
J Pharm Sci; 2019 Mar; 108(3):1085-1089. PubMed ID: 30339864
[TBL] [Abstract][Full Text] [Related]
34. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
37. Novobiocin is a potent inhibitor for human organic anion transporters.
Duan P; You G
Drug Metab Dispos; 2009 Jun; 37(6):1203-10. PubMed ID: 19282394
[TBL] [Abstract][Full Text] [Related]
38. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
39. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.
Guo M; Dai X; Hu D; Zhang Y; Sun Y; Ren W; Wang L
Poult Sci; 2016 Sep; 95(9):2129-35. PubMed ID: 27118859
[TBL] [Abstract][Full Text] [Related]
40. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
